Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The prescribing of lipid lowering drugs during a 1-year period: Analysis of 7490 health insurance files
Autore:
Krappweis, J; Aumann, D; Rentsch, A; Kirch, W;
Indirizzi:
Tech Univ Dresden, Fac Med, Inst Clin Pharmacol, D-01307 Dresden, Germany Tech Univ Dresden Dresden Germany D-01307 acol, D-01307 Dresden, Germany
Titolo Testata:
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
fascicolo: 2, volume: 9, anno: 2000,
pagine: 119 - 125
SICI:
1053-8569(200003/04)9:2<119:TPOLLD>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
HEART-DISEASE; PREVENTION; MORTALITY; RISK;
Keywords:
lipid lowering drugs; drug utilization; pharmacoepidemiology; prescription patterns;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Krappweis, J Tech Univ Dresden, Fac Med, Inst Clin Pharmacol, Fiedlerstr 27, D-01307 Dresden, Germany Tech Univ Dresden Fiedlerstr 27 Dresden Germany D-01307 many
Citazione:
J. Krappweis et al., "The prescribing of lipid lowering drugs during a 1-year period: Analysis of 7490 health insurance files", PHARMA D S, 9(2), 2000, pp. 119-125

Abstract

A study of prescription patterns by office-based physicians was conducted to analyse the use of lipid lowering drugs (LLD) in a Germany area of 1,768,874 inhabitants during a 1-year period. The prescription database consisted of health insurance fries from a random sampling of persons (n = 7490) belonging to a large statutory health insurance organization during 1993-1994. During the study period LLD were prescribed to about 2.8% of the study population. Fibrates (43.7%) were the most frequently prescribed drugs followed by HMG-CoA reductase inhibitors (29.5%) and nicotinic acid with derivatives (21.7%). The prevalence of treatment rose with increasing age peaking among 60- to 69-year-olds (7.5%). More than two-thirds of the patients were not treated continuously, receiving LLD for less than 6 months. Thus, in patients being treated with LLD, the therapy seems to be ineffective due to the short episodes of drug administration. The presence of hyperlipidaemia plus additional risk factors such as hypertension led to a higher rate of LLD prescriptions than that for hyperlipidaemia alone. Only half of the patients with a history of previous myocardial infarction and hyperlipidaemia received LLD. Furthermore, patients with hyperlipidaemia and additional risk factors such as arterial hypertension, diabetes mellitus and coronary heartdisease (CHD), in whom administration of LLD has often been shown to be effective, were by far too infrequently treated with these drugs. Copyright (C) 2000 John Wiley & Sons, Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 12:25:04